msn.com
Upadacitinib shows year-long benefit in perianal Crohn's disease
Cure8 flagged this item because the article title and available source metadata connect it to Crohn's disease, Inflammatory bowel disease, Upadacitinib, and JAK inhibitor. We do not yet have enough reliable article text to summarize the details.
This may be most useful for Adult patients following Crohn's disease, Inflammatory bowel disease, Upadacitinib, JAK inhibitor, and Perianal Disease.
What To Know
Cure8 does not have enough reliable source text to summarize this article yet. Based on the article title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, Upadacitinib, and JAK inhibitor. Use the original source link for the full details.
Trial findings can depend on who was enrolled, what outcomes were measured, and how long people were followed. The original source has the study details.
